Facebook      Twitter

blank

blank

ONLINE LEARNING CENTER
 

Women and HIV Treatment: Recently Reported Data (11HC03-DE02)

Sally Hodder, MD

 
 
 
 

Release Date: January 2009
Review Date: August 11, 2010
EXPIRED June 30, 2011
Activity Code: 11HC03-DE02

CREDIT IS NO LONGER AVAILABLE FOR THIS ACTIVITY.
Content is provided for informational purposes only.

As seen in the January 2009 edition of


ACTIVITY INFORMATION

Sponsor

Sponsored by the University of Medicine and Dentistry of New Jersey (UMDNJ), Center for Continuing and Outreach Education. This activity is supported by an educational grant from NJDHSS Division of HIV/AIDS Services through a MOA titled “Education and Training for Physicians and other Healthcare Professionals in the Diagnosis and Treatment of HIV/AIDS.”

Grantor Acknowledgement

This activity is supported by an educational grant from NJDHSS Division of HIV/AIDS Services through a MOA titled “Education and Training for Physicians and other Healthcare Professionals in the Diagnosis and Treatment of HIV/AIDS.

Target Audience

This activity is designed for physicians and nurses, and for other healthcare professionals in New Jersey who are involved in the care of women and/or persons with HIV/AIDS.

Statement of Need

Since the beginning of the HIV/AIDS epidemic, researchers, clinicians, patients and
advocates have raised concerns about whether women with HIV infection have
different disease manifestations or response to treatments. Women with HIV/AIDS
are now included in almost all clinical trials of HIV treatments, although there are
often restrictions related to protection of women and fetuses, for women of childbearing
age. The USDHSS HIV treatment guidelines published in January 2008
included a section titled “Considerations For Antiretroviral Use In Special Patient
Populations: HIV-Infected Women of Reproductive Age and Pregnant Women.” 1
Updated guidelines published in November 2008, referenced in this article,
continue the previous specific recommendations for treatment of women.2

1 Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents.
Department of Health and Human Services. January 29, 2008; 1-128. Available at: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.
2 Guidelines for the use of Antiretroviral Agents in HIV-1 Infected Adults and Adolescents, Department of Health and Human Services, November 3rd. 2008. Available at: http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf.

Learning Objectives

Upon completion of this learning activity, the reader should be able to:

  • Summarize the epidemiology of HIV infection in US women
  • Identify antiretroviral drug interactions with oral contraceptives and changes in pharmacokinetics that may occur with antiretroviral dosing in pregnancy
  • Describe recent antiretroviral clinical trial results, including comparison of outcomes among men and women

Method of Instruction

Participants should read the learning objectives and review the activity in its entirety. After reviewing the material, complete the self-assessment test which consists of a series of multiple-choice questions. Estimated time to complete this activity as designed is 1.25 hours.

Accreditation

EXPIRED- CE is no longer available for this activity. This content is being provided for informational purposes only.

Review

This activity was peer reviewed for relevance, accuracy of content, and balance of presentation by Patricia Kloser, MD, MPH; Debbie Y.Mohammed, MS, MPH, APRN-BC, and Brenda Christian, MEd, PA-C; and pilot tested for relevance and time required for participation by Kinshasa Morton, MD; Bonnie Abedini, MSN, RN; Mary C. Krug, RN, MSN, APN-C; and Kara Winslow, BSN, RN.

Faculty

Sally Hodder, MD, is Professor of Medicine, Vice Chair and Director of HIV Programs, Department of Medicine, New Jersey Medical School, University of Medicine and Dentistry of New Jersey. She previously served as the Vice President of U.S. Virology Medical Affairs at Bristol Myer Squibb. Dr. Hodder is a frequent contributor to Clinical Care Options webcasts and other medical education activities.She presented a poster on clinician provision of reproduction counseling to HIV-infected women at the 2008 International AIDS Conference in Mexico City.

Activity Director(s)/CME Academic Advisor(s)

Patricia Kloser, MD, MPH
UMDNJ-New Jersey Medical School

Planning Committee

  • Sindy Paul,MD,MPH, FACPM,New Jersey Dept. of Health and Senior Services
  • Debbie Y.Mohammed,MS,MPH, APRN-BC,UMDNJ-University Hospital
  • Linda Berezny, RN, BA,New Jersey Dept. of Health and Senior Services
  • Kimi Nakata,MSW,MPH,UMDNJ-CCOE

Faculty Disclosure Declarations

Dr. Hodder has disclosed the following: She was on the speaker’s bureau of BMS, has received grant/research support from BMS, Gilead, Tibotec and Pfizer; has been a consultant on advisory boards for: BMS, Gilead, Tibotec, and Boehringer- Ingelheim; and is a shareholder of Merck. Debbie Mohammed has disclosed the following: she is on the speaker’s bureaus of BMS and Gilead.

Conflicts of interest were resolved by review by Activity Director Patricia Kloser, MD, MPH.

The following have no financial relationships to disclose: Activity Director Patricia Kloser, MD, MPH; Planning committee members Sindy M. Paul, MD, MPH, FACPM; Linda Berezny, RN, BA; and Kimi Nakata, MSW, MPH (editor); content reviewer Brenda Christian, MEd, PA-C; and field testers: Kinshasa Morton, MD; Bonnie Abedini, BSN, MS; Mary C. Krug, RN, MSN, APN-C; and Kara Winslow, BSN, RN.

Off-Label Usage Disclosure

This activity contains information about commercial products that are unlabeled for use or investigational uses of products not yet approved:Vicriviroc is currently in Phase II/III clinical trials.Darunavir is in FDA Pregnancy Category B, and lopinavir/r is in FDA Pregnancy Category C; each should be used only if the potential benefit justifies the potential risk.

Disclaimer

The views expressed in this activity are those of the faculty. It should not be inferred or assumed that they are expressing the views of NJDHSS-Division of HIV/AIDS Services, UMDNJ, or any manufacturer of pharmaceuticals. The drug selection and dosage information presented in this activity are believed to be accurate. However, participants are urged to consult the full prescribing information on any agent(s) presented in this activity for recommended dosage, indications, contraindications, warnings, precautions, and adverse effects before prescribing any medication. This is particularly important when a drug is new or infrequently prescribed.

Copyright ©2009 UMDNJ-Center for Continuing and Outreach Education. All rights reserved including translation into other languages. No part of this activity may be reproduced or transmitted in any formor by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval systems, without permission in writing from UMDNJ-Center for Continuing and Outreach Education. Please direct CME related questions to UMDNJ at 973-972-4267 or email ccoe@ca.rutgers.edu.


 

© Copyright 2014, Rutgers, The State University of New Jersey, an equal opportunity, affirmative action institution.

Privacy Policy